Integrity Coronary Stent System    

Log In

Forgot Your Password?

Not a member? Click here!

Peripheral Intervention - Academic View
Laser Wire for CTO Recanalization
The PEPCAD Trials
When and How to Use Mechanical Devices
The MIV Polymer-Free Hydroxyapatite-Coated Sirolimus-Eluting Stent



Beat Blockers

Recent evidence has questioned the benefits of beta-blockers in secondary prevention. The current study has examined the clinical benefits of beta-blocker therapy in patients undergoing CABG, indicating that such agents are associated with a lower risk of long-term mortality and adverse CV events.

For more, click here




Paclitaxel-Coated Balloon

Restenosis following balloon angioplasty of peripheral arteries has remained the Achilles heel of peripheral intervention. The LEVANT-2 investigators examined the efficacy of paclitaxel-coated balloon angioplasty (PCBA) as compared with standard angioplasty (SA) in patients with symptomatic femoro-popliteal disease. PCBA was associated with greater primary patency and was non-inferior to SA with respect to safety.

For more, click here





Bridging in AF Patients

There is currently little consensus as to whether patients on anticoagulation for AF should have their anticoagulant stopped prior to invasive intervention. The BRIDGE investigators have indicated that forgoing bridging anticoagulation is non-inferior to bridging with low-molecular weight heparin for the prevention of thromboembolic complications and appears to reduce the risk of major bleeding.

For more, click here




Low ICD Implantation Rates Post MI

An ICD is recommended in post-MI patients with an LV ejection fraction ≤ 35% but not within 40 days of the MI. A retrospective observational study of 10,318 Medicare beneficiaries has shown that fewer than 1 in 10 eligible patients for an ICD received the device within 1 year after their MI despite the fact that ICD implantation was associated with lower mortality at 2 years.

For more, click here



Relationship between hospital PTCA volume and in-hospital outcomes: Is it still true 9 years later?
- Christian Spaulding, M.D., FACC, FESC
The EGO-BioFreedom Study
- Stephen Lee, MD
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
- George L. Zorn, III, MD
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement
- Thomas G. Gleason, MD
Valve Thrombosis After TAVR: Frequency, Clinical Recognition, and Management
- Azeem Latib, MD

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD
 Click here to visit the WEBEX archives

Cumulative Blood Pressure in Early Adulthood and Cardiac Dysfunction in Middle Age: The CARDIA Study.
S Kishi, et al.
JACC 2015; 65:2679-2687
Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions.
J Parsh.
JACC 2015; 65:2714-2723
Full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator: Primary Results of a Randomized Study.
M Gold, et al.
JACC 2015; 65:2581-2588
Remote Monitoring of Implantable Cardioverter-Defibrillators: A Systematic Review and Meta-Analysis of Clinical Outcomes.
N Parthiban, et al.
JACC 2015; 65:2591-2600
Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study.
L Fernandez-Friera, et al.
Circ 2015;131:2104-2113
Incidence, Management, and Immediate- and Long-Term Outcomes After Iatrogenic Aortic Dissection During Diagnostic or Interventional Coronary Procedures.
I Nunez-Gil, et al.
Circ 2015; 131:2114-2119
Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study.
E Svennberg, et al.
Circ 2015; 131:2176-2184
Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery.
H Zhang, et al.
Circ 2015; 131:2194-2201
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
K Rosenfield, et al.
NEJM 2015 Online
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.
J Douketis, et al.
NEJM 2015 Online
Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction.
S Pokorney, et al.
JAMA 2015; 313:2433-2440
5-Year Outcomes of Transcatheter Aortic Valve Replacement or Surgical Aortic Valve Replacement for High Surgical Risk Patients With Aortic Stenosis (PARTNER 1): A Randomised Controlled Trial.
M Mack, et al.
The Lancet 2015; 385:2477-2484
Ex-Vivo Perfusion of Donor Hearts for Human Heart Transplantation (PROCEED II): A Prospective, Open-Label, Multicentre, Randomised Non-Inferiority Trial.
A Ardehali, et al.
The Lancet 2015; 385:2577-2584

Poll Archives
The EGO-BioFreedom Study
Stephen WL LEE, M.D.
The CONTROL multi-center study
Israel Barbash, M.D.
The SORT OUT VII trial
Lisette Okkels Jensen, M.D.
The NOTION Trial
Lars Sondergaard, M.D., M.P.H.
Final Three-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer
Masahiro Natsuaki, M.D.
PRAGUE 13 trial
O. Hlinomaz, M.D.
Curzen N., M.D.
The Reservoir Clinical Trial
Rajeev K. Pathak, M.D.
The OCT Substudy of the TOTAL (ThrOmbecTomy versus PCI Alone) Trial
T Sheth, M.D.
The safety and long-term effect of renal artery denervation on blood pressure and renal function in real world patients with uncontrolled hypertension from the Global SYMPLICITY Registry
Felix Mahfoud, M.D.
Renal artery denervation for treatment of patients with obstructive sleep apnea and resistant hypertension: Results from the Global SYMPLICITY Registry
Dominik Linz, M.D.
Safety analysis of renal function following renal denervation: analysis from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry
Felix Mahfoud, M.D., PhD
Novel core wire technology on a zotarolimus eluting stent provides improved acute performance, including deliverability and radiopacity
Eulogio Garcia, M.D.
Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately 8000 Patients
Prof. Sigmund Silber, M.D.
Angiographic Sub-study of the TOTAL trial: a randomized trial of manual thrombectomy during PCI for STEMI
CB Overgaard, M.D., PhD
Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI
TOTAL Trial Investigators
The CoreValve ADVANCE II Study
Georg Nickenig, M.D.
Three-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expending bioprosthesis
Sabine Bleiziffer, M.D.
6-Month Outcomes Following Transcatheter Aortic Valve Implantation With a Novel Repositionable Self-Expanding Bioprosthesis
Ian T. Meredith, MBBS, PhD
An All-comers Randomized Clinical Trial Comparing Transcatheter with Surgical Aortic Valve Replacement in Patients with Aortic Valve Stenosis
Lars Sondergaard, M.D., M.P.H.

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD

Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2015 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2015, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb